Cannabinoids: Novel therapies for arthritis?

Future Medicinal Chemistry

Volumn 4, Issue 6, 2012, Pages 713-725

  Dunn, Sara L ^a   Wilkinson, J Mark ^b   Crawford, Aileen ^c   Le Maitre, Christine L ^a   Bunning, Rowena A D ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AJULEMIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; CORTICOSTEROID; DEXANABINOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOSAMINE SULFATE; GPR 55; HYALURONIC ACID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NUTRACEUTICAL; O 1602; PALMIDROL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIMONABANT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT ARTHRITIS; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICULAR CARTILAGE; B LYMPHOCYTE; CARTILAGE CELL; CARTILAGE DEGENERATION; CHONDROPROTECTION; DRUG BINDING; DRUG MECHANISM; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; HUMAN; JOINT INJURY; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; T LYMPHOCYTE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CANNABINOIDS; CARTILAGE; HUMANS; OSTEOARTHRITIS;

EID: 84860248867     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.20     Document Type: Review

References (117)

1. Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res. Ther. 11(3), 224 (2009).
2. Otero M, Goldring MB. Cells of the synovium in rheumatoid arthritis. Chondrocytes. Arthritis Res. Ther. 9(5), 220 (2007).
3. Rannou F, Francois M, Corvol MT et al. Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine 73(1), 29-36 (2006).
4. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr. Opin. Rheumatol. 23(5), 471-478 (2011).
5. Poole AR, Kojima T, Yasuda T et al. Composition and structure of articular cartilage: A template for tissue repair. Clin. Orthop. Relat. Res. 391(Suppl.), S26-S33 (2001).
6. Sun HB. Mechanical loading, cartilage degradation, and arthritis. Ann. NY Acad. Sci. 1211, 37-50 (2010).
7. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 43(9), 1916-1926 (2000).
8. Mitchell PG, Magna HA, Reeves LM et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J. Clin. Invest. 97(3), 761-768 (1996).
9. Jones GC, Riley GP. ADAMTS proteinases. A multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res. Ther. 7(4), 160-169 (2005).
10. Little CB, Meeker CT, Golub SB et al. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J. Clin. Invest. 117(6), 1627-1636 (2007).
11. Cawston TE, Young DA. Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res. 339(1), 221-235 (2010).
12. Patwari P, Cook MN, DiMicco MA et al. Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: Interaction with exogenous cytokines. Arthritis Rheum. 48(5), 1292-1301 (2003).
13. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin. Orthop. Relat. Res. 427(Suppl.), S27-S36 (2004).
14. Goldring MB, Goldring SR. Osteoarthritis. J. Cell. Physiol. 213(3), 626-634 (2007).
15. Billinghurst RC, Wu W, Ionescu M et al. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum. 43(3), 664-672 (2000).
16. van Meurs JB, van Lent PL, Holthuysen AE et al. Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum. 42(6), 1128-1139 (1999).
17. Goldring MB, Otero M, Tsuchimochi K et al. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann. Rheum. Dis. 67(Suppl. 3), iii75-iii82 (2008).
18. Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr. Opin. Rheumatol. 10(3), 263-268 (1998).
19. Taskiran D, Stefanovic-Racic M, Georgescu H et al. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem. Biophys. Res. Commun. 200(1), 142-148 (1994).
20. Hashimoto S, Takahashi K, Amiel D et al. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. Arthritis Rheum. 41(7), 1266-1274 (1998).
21. Amin AR, Dave M, Attur M et al. COX-2, NO, and cartilage damage and repair. Curr. Rheumatol. Rep. 2(6), 447-453 (2000).
22. Westra J, Limburg PC. p38 mitogen-Activated protein kinase (MAPK) in rheumatoid arthritis. Mini Rev. Med. Chem. 6(8), 867-874 (2006).
23. Marcu KB, Otero M, Olivotto E et al. NF-kappaB signaling. multiple angles to target OA. Curr. Drug Targets 11(5), 599-613 (2010).
24. Liacini A, Sylvester J, Li WQ et al. Induction of matrix metalloproteinase-13 gene expression by TNF-Alpha is mediated by MAP kinases, AP-1, and NF-kB transcription factors in articular chondrocytes. Exp. Cell Res. 288(1), 208-217 (2003).
25. Liacini A, Sylvester J, Li WQ et al. Inhibition of interleukin-1- stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kB (NF-kB) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 21(3), 251-262 (2002).
26. Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells. requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res. 29(21), 4361-4372 (2001).
27. Mengshol JA, Vincenti MP, Coon CI et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-Terminal kinase, and nuclear factor kB. differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 43(4), 801-811 (2000).
28. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis. integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 4(3), 157-164 (2002).
29. Doan T, Massarotti E. Rheumatoid arthritis. An overview of new and emerging therapies. J. Clin. Pharmacol. 45(7), 751-762 (2005).
30. Sokka T, Envalds M, Pincus T. Treatment of rheumatoid arthritis. A global perspective on the use of antirheumatic drugs. Mod. Rheumatol. 18(3), 228-239 (2008).
31. Gaujoux-Viala C, Smolen JS, Landewe R et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs. A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 69(6), 1004-1009 (2010).
32. Tak PP, Kalden JR. Advances in rheumatology. new targeted therapeutics. Arthritis Res. Ther. 13(Suppl. 1), S5 (2011).
33. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. A systematic review. J. Rheumatol. 36(6), 1118-1125 (2009).
34. Nurmohamed MT. Newer biological agents in the treatment of rheumatoid arthritis. do the benefits outweigh the risks? Drugs 69(15), 2035-2043 (2009).
35. Blake DR, Robson P, Ho M et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex®) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45(1), 50-52 (2006).
36. Goldring MB. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract. Res. Clin. Rheumatol. 20(5), 1003-1025 (2006).
37. Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis. destruction or repair? Nat. Clin. Pract. Rheumatol. 4(3), 128-135 (2008).
38. Joy JE, Watson SJ, Benson, JA. Marijuana and medicine; accessing the science base. National Academy of Sciences, Washington DC, USA (1999).
39. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 7(3), E625-E654 (2005).
40. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58(3), 389-462 (2006).
41. Richardson D, Pearson RG, Kurian N et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 10(2), R43 (2008).
42. Mbvundula EC, Rainsford KD, Bunning RA. Cannabinoids in pain and inflammation. Inflammopharmacology 12(2), 99-114 (2004).
43. Croxford JL, Yamamura T. Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases? J. Neuroimmunol. 166(1-2), 3-18 (2005).
44. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5(5), 400-411 (2005).
45. Zurier RB, Rossetti RG, Lane JH et al. Dimethylheptyl-THC-11 oic acid. A nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum. 41(1), 163-170 (1998).
46. Malfait AM, Gallily R, Sumariwalla PF et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-Arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 97(17), 9561-9566 (2000).
47. Sumariwalla PF, Gallily R, Tchilibon S et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 50(3), 985-998 (2004).
48. Zurier RB, Rossetti RG, Burstein SH et al. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem. Pharmacol. 65(4), 649-655 (2003).
49. Johnson DR, Stebulis JA, Rossetti RG et al. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J. Cell. Biochem. 100(1), 184-190 (2007).
50. Selvi E, Lorenzini S, Garcia-Gonzalez E et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin. Exp. Rheumatol. 26(4), 574-581 (2008).
51. Mbvundula EC, Bunning RA, Rainsford KD. Arthritis and cannabinoids. HU-210 and Win-55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in vitro. J. Pharm. Pharmacol. 58(3), 351-358 (2006).
52. Mbvundula EC, Bunning RAD, Rainsford KD. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem. Pharmacol. 69(4), 635-640 (2005).
53. Tanasescu R, Constantinescu CS. Cannabinoids and the immune system. An overview. Immunobiology 215(8), 588-597 (2010).
54. Idris AI, Ralston SH. Cannabinoids and bone. friend or foe? Calcif. Tissue Int. 87(4), 285-297 (2010).
55. Matsuda LA, Lolait SJ, Brownstein MJ et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284), 561-564 (1990).
56. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441), 61-65 (1993).
57. Howlett AC. Cannabinoid receptor signaling. Handb. Exp. Pharmacol. (168), 53-79 (2005).
58. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 68-69, 619-631 (2002).
59. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands. An overview. Int. J. Obes. (Lond) 30(Suppl. 1), S13-S18 (2006).
60. Andersson J, Sophocleous A, Zhou Y et al. Expression of cannabinoid receptors by human articular chondrocytes. Bone 48(Suppl. 2), S141-S141 (2011).
61. Brown AJ. Novel cannabinoid receptors. Br. J. Pharmacol. 152(5), 567-575 (2007).
62. Bisogno T, Hanus L, De Petrocellis L et al. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134(4), 845-852 (2001).
63. Smart D, Jerman JC. Anandamide. An endogenous activator of the vanilloid receptor. Trends Pharmacol. Sci. 21(4), 134 (2000).
64. Costa B, Giagnoni G, Franke C et al. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br. J. Pharmacol. 143(2), 247-250 (2004).
65. McPartland JM, Matias I, Di Marzo V et al. Evolutionary origins of the endocannabinoid system. Gene 370, 64-74 (2006).
66. Sharir H, Abood ME. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther. 126(3), 301-313 (2010).
67. Ryberg E, Larsson N, Sjogren S et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152(7), 1092-1101 (2007).
68. Kapur A, Zhao P, Sharir H et al. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem. 284(43), 29817-29827 (2009).
69. Schuelert N, McDougall JJ. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci. Lett. 500(1), 72-76 (2011).
70. Whyte LS, Ryberg E, Sims NA et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl Acad. Sci. USA 106(38), 16511-16516 (2009).
71. Oka S, Nakajima K, Yamashita A et al. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 362(4), 928-934 (2007).
72. O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-Activated receptors. potential for modulation of inflammatory disease. Immunobiology 215(8), 611-616 (2010).
73. Desvergne B, Wahli W. Peroxisome proliferator-Activated receptors. nuclear control of metabolism. Endocr. Rev. 20(5), 649-688 (1999).
74. O'Sullivan SE. Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-Activated receptors. Br. J. Pharmacol. 152(5), 576-582 (2007).
75. Bordji K, Grillasca JP, Gouze JN et al. Evidence for the presence of peroxisome proliferator-Activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. J. Biol. Chem. 275(16), 12243-12250 (2000).
76. Fahmi H, Di Battista JA, Pelletier JP et al. Peroxisome proliferators-Activated receptor gamma activators inhibit interleukin-1beta- induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum. 44(3), 595-607 (2001).
77. Afif H, Benderdour M, Mfuna-Endam L et al. Peroxisome proliferator-Activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1beta in articular chondrocytes. Arthritis Res. Ther. 9(2), R31 (2007).
78. Boyault S, Simonin MA, Bianchi A et al. 15-deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett. 501(1), 24-30 (2001).
79. Fahmi H, Pelletier JP, Di Battista JA et al. Peroxisome proliferator-Activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. Osteoarthritis Cartilage 10(2), 100-108 (2002).
80. Shao YY, Wang L, Hicks DG et al. Expression and activation of peroxisome proliferator-Activated receptors in growth plate chondrocytes. J. Orthop. Res. 23(5), 1139-1145 (2005).
81. Ambrosio AL, Dias SM, Polikarpov I et al. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-Activated receptor gamma. J. Biol. Chem. 282(25), 18625-18633 (2007).
82. Liu J, Li H, Burstein SH et al. Activation and binding of peroxisome proliferator-Activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 63(5), 983-992 (2003).
83. Clockaerts S, Bastiaansen-Jenniskens YM, Feijt C et al. Peroxisome proliferator activated receptor alpha activation decreases inflammatory and destructive responses in osteoarthritic cartilage. Osteoarthritis Cartilage 19(7), 895-902 (2011).
84. Bianchi A, Moulin D, Sebillaud S et al. Contrasting effects of peroxisome-proliferator-Activated receptor (PPAR)gamma agonists on membrane-Associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes: Evidence for PPARgamma-independent inhibition by 15-deoxy-Delta12,14prostaglandin J2. Arthritis Res. Ther. 7(6), R1325-37 (2005).
85. Stebulis JA, Johnson DR, Rossetti RG et al. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 83(19-20), 666-670 (2008).
86. Lee JH, Yu SM, Yoon EK et al. 15-deoxy-D12,14-prostaglandin J2 regulates dedifferentiation through peroxisome proliferator-Activated receptor-gamma- dependent pathway but not COX-2 expression in articular chondrocytes. J. Korean Med. Sci. 22(5), 891-897 (2007).
87. Poleni PE, Etienne S, Velot E et al. Activation of PPARs alpha, beta/delta, and gamma impairs TGF-beta1-induced collagens' production and modulates the TIMP-1/MMPs balance in three-dimensional cultured chondrocytes. PPAR Res. 2010, 635912 (2010).
88. Moulin D, Bianchi A, Boyault S et al. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-Activated receptor beta/delta-dependent mechanism. Arthritis Rheum. 52(3), 759-769 (2005).
89. Francois M, Richette P, Tsagris L et al. Activation of the peroxisome proliferator-Activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-Treated chondrocytes. Arthritis Rheum. 54(4), 1233-1245 (2006).
90. Lo Verme J, Fu J, Astarita G et al. The nuclear receptor peroxisome proliferator-Activated receptor-Alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67(1), 15-19 (2005).
91. Sun Y, Alexander SP, Kendall DA et al. Cannabinoids and PPARalpha signalling. Biochem. Soc. Trans. 34(Pt 6), 1095-1097 (2006).
92. Sun Y, Bennett A. Cannabinoids. A new group of agonists of PPARs. PPAR Res. 2007, 23513 (2007).
93. Bouaboula M, Hilairet S, Marchand J et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 517(3), 174-181 (2005).
94. Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 11(1), 109-119 (2009).
95. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids. Evidence for new players. AAPS J. 8(2), E298-E306 (2006).
96. Di Marzo V, Bisogno T, De Petrocellis L et al. Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids. Curr. Med. Chem. 6(8), 721-744 (1999).
97. Piomelli D, Beltramo M, Giuffrida A et al. Endogenous cannabinoid signaling. Neurobiol. Dis. 5(6), 462-473 (1998).
98. Dinh TP, Carpenter D, Leslie FM et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl Acad. Sci. USA. 99(16), 10819-10824 (2002).
99. Deutsch DG, Ueda N, Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids 66(2-3), 201-210 (2002).
100. Sancho R, Calzado MA, Di Marzo V et al. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol. Pharmacol. 63(2), 429-438 (2003).
101. Beg AA, Finco TS, Nantermet PV et al. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha. A mechanism for NF-kappa B activation. Mol. Cell. Biol. 13(6), 3301-3310 (1993).
102. Fan Z, Yang H, Bau B et al. Role of mitogen-Activated protein kinases and NF-kappaB on IL-1beta-induced effects on collagen type II, MMP-1 and 13 mRNA expression in normal articular human chondrocytes. Rheumatol. Int. 26(10), 900-903 (2006).
103. Mihara K, Almansa C, Smeets RL et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis. A comparison with neutralization of mouse TNF-Alpha. Br. J. Pharmacol. 154(1), 153-164 (2008).
104. Sondergaard BC, Schultz N, Madsen SH et al. MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation - divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthritis Cartilage 18(3), 279-288 (2010).
105. Saklatvala J. Inflammatory signaling in cartilage. MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr. Drug Targets 8(2), 305-313 (2007).
106. Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: The kinase inhibitors. Rheumatology (Oxford) 50(9), 1542-1550 (2011).
107. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 168, 299-325 (2005).
108. Ashton JC, Wright JL, McPartland JM et al. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr. Med. Chem. 15(14), 1428-1443 (2008).
109. Kinsey SG, Naidu PS, Cravatt BF et al. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol. Biochem. Behav. 99(4), 718-725 (2011).
110. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: Therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs 11(1), 51-62 (2010).
111. Siegmund SV, Seki E, Osawa Y et al. Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J. Biol. Chem. 281(15), 10431-10438 (2006).
112. Mukhopadhyay P, Horvath B, Rajesh M et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic. Biol. Med. 50(1), 179-195 (2011).
113. Nomura DK, Morrison BE, Blankman JL et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334(6057), 809-813 (2011).
114. Ahmed AS, Li J, Erlandsson-Harris H et al. Suppression of pain and joint destruction by inhibition of the proteasome system in experimental osteoarthritis. Pain 153(1), 18-26 (2011).
115. Idris AI, van't Hof RJ, Greig IR et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. 11(7), 774-779 (2005).
116. Idris AI, Sophocleous A, Landao-Bassonga E et al. Cannabinoid receptor type 1 protects against age- related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metabolism 10(2), 139-147 (2009).
117. Ofek O, Karsak M, Leclerc N et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl Acad. Sci. USA 103(3), 696-701 (2006).